 The primary endpoint will be the UPDRS III at 12 months end of the cross over, and subsequently at 18 and 30 months. We will compare the clinical results with the precise site of the stimulating electrodes and we will try to correlate the clinical results with the amount of inhibition induced by motor cortex stimulation. 